NCT05334823

A Phase II Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL

Study Summary

This is a phase II clinical study to evaluate the safety and efficacy of pCAR-19 B cell autologous infusion preparation in the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.

Interested in this trial?

Submit an Inquiry

Interventions

pCAR-19B cellsBIOLOGICAL
Drug: pCAR-19B cells; Administration method: intravenous infusion; Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.

Study Locations

FacilityCityStateCountry
Beijing Children's Hospital.Capital Medical UniversityBeijingBeijing MunicipalityChina
Beijing GoBroad Boren HospitalBeijingBeijing MunicipalityChina
Children's Hospital of Chongqing Medical UniversityChongqingChongqing MunicipalityChina
Shenzhen Children's HospitalShenzhenGuangdongChina
Pediatric Hematology department of Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and TechnologyWuhanHubeiChina
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and TechnologyWuhanHubeiChina
Xiehe Hospital affiliated to Tongji Medical College of Huazhong University of Science and TechnologyWuhanHubeiChina
The Second Xiangya Hospital, Central South UniversityChangshaHunanChina
Affiliated Drum Tower Hospital, Medical School of Nanjing UniversityNanjingJiangsuChina
Jiangsu Province HospitalNanjingJiangsuChina
Children's Hospital Of Soochow UniversitySuzhouJiangsuChina
The First Affiliated Hospital of Nanchang UniversityNanchangJiangxiChina
West China Second University Hospital,Sichuan UniversityChengduSichuanChina
Institute Of Hematology&Blood Diseases Hospital,Chinese Academy Of Medicai SciencesTianjinTianjin MunicipalityChina
Children's Hospital, Zhejiang University School of MedicineHangzhouZhejiangChina
The First Affiliated Hospital of Zhengzhou UniversityHenanZhengzhouChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: October 12, 2026